American chemicals maker Cambrex has announced its active pharmaceutical ingredient (API) manufacturing facility has completed a successful FDA inspection.
Malaysia is keen to attract Indian biopharm companies and is offering incentives and infrastructure to encourage firms to establish manufacturing operations, according to local media reports.
Indian API manufacturer Shasun Chemicals and Drugs turned a previous loss into profit for Q4 of this year as it seeks to make a dent in the biosimilar manufacturing sector.
India-based Surya Pharmaceuticals is planning to raise Rs 500 crore ($100m) to fund construction of an active pharmaceutical ingredient (API) production plant, according to local media reports.
New research could make it possible for scientists to use silicon particles as an effective drug delivery system that enables fragile small interfering RNA (siRNA) based drugs to be directly transported to the disease’s location.
Lanxess has signalled its intentions for the future by investing €35m ($43m) to expand its German Basic Chemicals business unit in a move that is set to make the firm one of Europe’s biggest active pharmaceutical ingredients (API) producers.
Cevec has exclusively licensed its transient CAP-T cell expression technology to Pevion for the manufacture and commercialisation of a protein antigen to vaccinate against an infectious disease.
DPT Laboratories has added bulk production and packaging capacity at its liquid and semi-solids plant in San Antonio, Texas in a continuation of its recent manufacturing reorganisation.
AMRI is reducing its US workforce 10 per cent and halting operations in one R&D lab at its facility in Rensselaer, New York as “softness” in the domestic market continues beyond its expectations.
Adcock Ingram recorded an 11 per cent rise in profit in the first half of 2010 and is looking to continue this upwards trend through manufacturing expansions, plus local and overseas acquisitions.
US CMO Contract Pharmaceuticals (CPL) to close Buffalo plant by the end of 2011 on weak demand it attributes to pharmaceutical industry outsourcing cuts in downturn.
Invida has acquired a stake in Indonesia-based MUGI, giving it the local manufacturing presence needed to offer partners access to “a vast untapped market”.
Eisai has opened a $100m (€81m), 65,000 sq ft commercial manufacturing and drug development site for intravenous treatments in Research Triangle Park (RTP), North Carolina, US.
An increase in demand for rayon fabric in China has led to higher prices for microcrystalline cellulose, an excipient for pharmaceuticals and a stabilizer for foods, drinks and personal care products.
Pfizer plans to close eight manufacturing sites and reduce operations at a further six by the end of 2015, leading to 6,000 job losses, as part of its reorganisation after acquiring Wyeth.
Eurand says Zenpap important to Q1 growth that recent FDA move provides the drug with significant potential for further expansion in cystic fibrosis (CF) market
Administration of Levitra (vardenafil) can increase Herceptin (trastuzumab) delivery to brain metastases, but not surrounding healthy tissue, increasing survival in mice, according to research.
Albany Molecular Research (AMRI) says Q1 decline is due to “soft” demand for contract manufacturing services and trial materials, but is still confident of full-year growth.
Cambrex has posted a 55 per cent drop in operating profit in the first quarter, underpinned by the timing of orders, disruption to a customer’s supply chain and lower pricing of certain generic APIs.
Rheumatoid arthritis (RA) sufferers may soon have a new treatment delivery option thanks to US delivery specialist Antares Pharma’s partnership with Canadian injectables specialist Uman Pharma.
EyeGate Pharma is collaborating with GlaxoSmithKline (GSK) to evaluate the delivery if several of the big pharma’s therapies using an ocular delivery system.
US firm SAFC plans to turn its dry powder culture media manufacturing plant in Lenexa, Kansas into a “centre of excellence” with $6.3m (€4.7m) capacity expansion.
The incoming Xcellerex CEO plans to move the company from validation to penetration, boosting revenues and client base, and invest in the contract manufacturing side of the business.
Colorcon has acquired excipient business NP Pharm, adding sugar spheres to its portfolio and production capacity that will become “an integral part” of its manufacturing network.
Capacity at Blu Pharmaceutical’s recently acquired solid dosage production plant in Puerto Rico is set to expand considerable over the next three years according to company president Bill Luster.
A project bringing together researchers from academia and pharma companies, including GSK and AZ, has received a £709,000 ($1.09m) grant to create crystals using continuous flow production.
in-PharmaTechnologist presents exclusive interactive maps of pharma manufacturing facilities in India, detailing the number of bulk drug and formulation facilities in each region of the country.
The US Food and Drug Administration (FDA) has issued Apotex with another warning letter about cGMP violations at two plants explaining the firm’s response to previous warnings “is inadequate and lacks sufficient corrective actions.”
Archimica has entered into an exclusive distribution agreement with a Merck KGaA subsidiary to provide building blocks and special reagents for organic synthesis.
US delivery specialist Penwest is to apply its Timerx tech to “complex” generic pharmaceuticals in a development and commercialisation pact with non-branded drugmaker Alvogen.
The drug industry will gain new options for sterile contract development and manufacturing in the near future with DPT Laboratories, NextPharma and Vetter each working on new dedicated units.
Winsunny Pharma has exclusively licensed NMT’s HGCP technology, which produces APIs in low micron and nano-sized range, to manufacture a hyperlipidemia-controlling drug in China.
Thermo Fisher Scientific will take charge of clinical trial material production at Eli Lilly’s research technology facility in Indianapolis as the pharmaceutical firm further reduces in-house capacity to cut costs.
